Credit Suisse AG Increases Position in Retrophin, Inc. (RTRX)

Credit Suisse AG boosted its stake in shares of Retrophin, Inc. (NASDAQ:RTRX) by 8.4% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 57,025 shares of the biopharmaceutical company’s stock after buying an additional 4,407 shares during the period. Credit Suisse AG owned about 0.15% of Retrophin worth $1,052,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently modified their holdings of RTRX. TIAA CREF Investment Management LLC raised its position in shares of Retrophin by 196.0% in the first quarter. TIAA CREF Investment Management LLC now owns 636,545 shares of the biopharmaceutical company’s stock valued at $11,751,000 after buying an additional 421,515 shares in the last quarter. FMR LLC raised its position in shares of Retrophin by 24.8% in the first quarter. FMR LLC now owns 1,958,875 shares of the biopharmaceutical company’s stock valued at $36,161,000 after buying an additional 389,714 shares in the last quarter. Renaissance Technologies LLC raised its position in shares of Retrophin by 783.3% in the first quarter. Renaissance Technologies LLC now owns 364,800 shares of the biopharmaceutical company’s stock valued at $6,734,000 after buying an additional 323,500 shares in the last quarter. Dimensional Fund Advisors LP raised its position in shares of Retrophin by 53.7% in the first quarter. Dimensional Fund Advisors LP now owns 553,702 shares of the biopharmaceutical company’s stock valued at $10,221,000 after buying an additional 193,432 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its position in shares of Retrophin by 14,062.4% in the first quarter. JPMorgan Chase & Co. now owns 131,852 shares of the biopharmaceutical company’s stock valued at $2,434,000 after buying an additional 130,921 shares in the last quarter.

Retrophin, Inc. (RTRX) traded down 0.42% during midday trading on Monday, hitting $23.76. The stock had a trading volume of 92,845 shares. The company’s market cap is $912.03 million. Retrophin, Inc. has a 1-year low of $15.55 and a 1-year high of $24.57. The company’s 50 day moving average is $20.41 and its 200 day moving average is $19.18.

Retrophin (NASDAQ:RTRX) last released its quarterly earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.24) by $0.10. Retrophin had a negative net margin of 48.74% and a negative return on equity of 7.31%. The business had revenue of $38.80 million during the quarter, compared to analyst estimates of $37.36 million. During the same quarter in the previous year, the firm posted $0.07 earnings per share. The firm’s quarterly revenue was up 16.5% on a year-over-year basis. On average, equities analysts anticipate that Retrophin, Inc. will post ($1.13) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “[[title]]” was first posted by [[site]] and is owned by of [[site]]. If you are reading this piece of content on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The original version of this piece of content can be viewed at [[permalink]].

RTRX has been the topic of several research reports. Zacks Investment Research lowered Retrophin from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, May 3rd. TheStreet upgraded Retrophin from a “d” rating to a “c-” rating in a research note on Friday, May 12th. ValuEngine upgraded Retrophin from a “sell” rating to a “hold” rating in a research note on Monday, July 17th. Finally, BidaskClub upgraded Retrophin from a “hold” rating to a “buy” rating in a research note on Wednesday, August 16th. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $32.25.

In other news, COO Neil F. Mcfarlane sold 1,378 shares of Retrophin stock in a transaction that occurred on Wednesday, August 16th. The shares were sold at an average price of $22.50, for a total value of $31,005.00. Following the completion of the sale, the chief operating officer now directly owns 13,622 shares in the company, valued at $306,495. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. 2.41% of the stock is currently owned by insiders.

Retrophin Company Profile

Retrophin, Inc is a biopharmaceutical company. The Company is focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. The Company sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin).

Want to see what other hedge funds are holding RTRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Retrophin, Inc. (NASDAQ:RTRX).